---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009744"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:52:03.980384+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome reports preliminary 4Q and FY 2025 net product revenue of $196M and $638.5M, up 65% and 66% YoY

## Summary
- Total preliminary 4Q net product revenue $196.0M (+65% YoY); full year $638.5M (+66% YoY).
- AUVELITY net product sales: $155.1M (4Q), $507.1M (FY).
- SUNOSI net product revenue: $36.7M (4Q), $124.8M (FY).
- SYMBRAVO net product sales (launched June 2025): $4.1M (4Q), $6.6M (FY).

## SEC filing metadata
- accession: 0001193125-26-009744
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/0001193125-26-009744-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000119312526009744/axsm-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009744
- JSON: https://secwatch.observer/filing/0001193125-26-009744.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009744.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.